← All trials
NCT07008547
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 30, 2024
- Primary completion
- Mar 28, 2025
- Completion date
- Mar 11, 2026
- First posted
- Jun 6, 2025
- Last posted
- Jun 6, 2025
- Enrollment
- 202
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- BiocadLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.